Cala Health’s kIQ Plus now offers three stimul

An up to $28.

Adjusting for how advanced patients’ disease w

German biotech MODAG won for pairing a CE-marked

Buck Institute’s Eric Verdin joins clinic lead

Veradermics announced it will host a conference c

New clinical data for XellSmart’s off-the-shelf

BodySpec’s new storefront targets muscle loss

VectorY is growing PIONEER-ALS from 12 to 36 par

A Censuswide survey commissioned by PortionIQ fi

Jupiter Neurosciences also hired an adviser to e

A quick digital memory test and a lab assay for

Forget the diagnosis count.

Mission Therapeutics has dosed the first patient

Oxford Healthspan has launched Primeadine GF Sper

Elysium has launched Balance, a supplement aimed

Fractyl Health reported positive six-month toplin

Renue by Science has launched the Renue Research

A new preprint links the company’s cell therap

The whole-body scan company is launching a resea

The company added hormone therapy to its platfor

All three Phase 3 trials of the weekly shot ribu

Patent cliffs and falling R&D productivity push

Monte Rosa’s NEK7-targeting drug pulled severa

Tenvie Therapeutics announced on 13 October 2026

Digbi Health expanded its precision biology teleh

Inmune Bio and Quantum Computing Inc.

Reservoir offers the chance to preserve today’

Diagnostic Imaging Centers of Texas will pair MR

A Lancet Neurology study of 130 blood proteins i

Mighty Therapeutics and the University of Washin

Lovehoney’s hormone-free MenoPulse device laun

Rapalogix Health announced the publication of a p

Sironax said on 13 October that it has reached ab

The Rhode Island Life Science Hub and Cognito The

Rona Therapeutics granted Roche an exclusive worl

Forecast for rapid growth by 2033, with disease-

Arvinas presented early biomarker data on ARV-10

Better U and Evernow have joined forces to pair

QIMA Life Sciences launches SQINGEVITY, bringing

Small open-label study of ATR-258 saw fat loss,

IBio’s eight-week obese nonhuman primate study

The United States Patent and Trademark Office has

United Therapeutics will present two oral and fiv

Boehringer Ingelheim widens its kidney-disease p

A two-year partnership with Ultrahuman aims to c

GPX4-targeting therapy reduces epigenetic age ma

Rubedo Life Sciences released Phase 1b clinical f

Function and Google Health announced a partnershi

Immorta Bio completed planned preclinical studies